You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
McKesson
Dow
Colorcon
McKinsey

Last Updated: February 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,387,615


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,387,615 protect, and when does it expire?

Patent 8,387,615 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-five patent family members in twenty-nine countries.

Summary for Patent: 8,387,615
Title:Inhaler cap strap
Abstract: An inhaler (1) for dispensing doses of medicament from a container under user activation said inhaling which comprises a body (7) which includes a mouthpiece (5) through which the medicament is dispensed and a cap (2) which can be place in a position to substantially occlude the mouthpiece (5). The cap (2) is attached to said body (7) by a strap (3) which pivots from said body (7), said cap (2) being arranged to slide on the strap (3) such that the cap (2) must translate away from the mouthpiece (5) prior to the pivoting of the strap (3).
Inventor(s): Bunce; Martin (Marlborough, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/579,481
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 8,387,615

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,387,615

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0303029Nov 17, 2003
PCT Information
PCT FiledNovember 10, 2004PCT Application Number:PCT/SE2004/001631
PCT Publication Date:May 26, 2005PCT Publication Number: WO2005/046774

International Family Members for US Patent 8,387,615

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 047124   Start Trial
Austria 369167   Start Trial
Australia 2004289156   Start Trial
Brazil PI0416636   Start Trial
Canada 2545445   Start Trial
China 100493643   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
McKinsey
Baxter
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.